Phase 2 of coronavirus vaccine human trials may begin in spring – CNBC
|CNBC reports that a phase 2 of coronavirus vaccine human trials may begin in spring, Moderna chairman says, resultant to out a specific date on things as it is a very dynamic situation.
CNBC's Key points
- The first human trial of a vaccine to prevent the new coronavirus could advance to the next step this spring, Moderna Chairman Noubar Afeyan said Thursday.
- “We’ll enter hopefully phase 2 trials, we expect that to happen in the spring, perhaps early summer,” Afeyan told CNBC’s Meg Tirrell.
- “It’s difficult to put a specific date on things just because it’s a very dynamic situation,” he added.
EUR/USD price analysis
The EUR/USD pair is pressuring the 61.8% retracement of its latest bullish run, maintaining its negative bias ahead of the Asian opening. In the 4-hour chart, the pair is extending its slide below all of its moving averages, with the 20 SMA moving below the larger ones, although all of them still confined to a tight range. Technical indicators in the mentioned chart stand at daily lows although losing their bearish strength. Anyway, the risk remains skewed to the downside, with the market looking to re-test the yearly low at 1.0635
– Valeria Bednarik, Chief Analyst at FXStreet explained.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.